Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Case Report of a patient with LGL-Leukemia who Developed a Leptomeningeal Lymphomatosis
Schallegger K, Brügge D, Hitz F, Hundsberger T, Cathomas R, Plasswilm L (2012). Case Report of a patient with LGL-Leukemia who Developed a Leptomeningeal Lymphomatosis.
Apr 19, 2012Case Report of a patient with LGL-Leukemia who Developed a Leptomeningeal Lymphomatosis
Apr 19, 2012SASRO 2012
Schallegger K, Brügge Detlef, Hitz Felicitas, Hundsberger Thomas, Cathomas R, Plasswilm Ludwig
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
von Minckwitz G, Mehta K, Nekljudova V, Denkert C, Konecny G, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Eiermann W, Gerber B, Fasching P, Eidtmann H, Costa S, Blohmer J, Untch M, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796-804.
Apr 16, 2012Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
Apr 16, 2012J Clin Oncol 2012; 30:1796-804
von Minckwitz Gunter, Mehta Keyur, Nekljudova Valentina, Denkert Carsten, Konecny Gottfried E, Kaufmann Manfred, Jackisch Christian, Huober Jens, Hilfrich Jörn, Eiermann Wolfgang, Gerber Bernd, Fasching Peter A, Eidtmann Holger, Costa Serban D, Blohmer Jens-Uwe, Untch Michael, Loibl Sibylle
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer
Jörger M, ess s, Dehler S, Savidan A, Bouchardy C, Frick H, Konzelmann I, Thürlimann B. A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer. Swiss Med Wkly 2012; 142:w13571.
Apr 11, 2012A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer
Apr 11, 2012Swiss Med Wkly 2012; 142:w13571
Jörger Markus, ess silvia, Dehler Silvia, Savidan Anita, Bouchardy Christine, Frick Harald, Konzelmann Isabelle, Thürlimann Beat
Therapeutic options for advanced prostate cancer: 2011 update
Omlin A, de Bono J. Therapeutic options for advanced prostate cancer: 2011 update. Curr Urol Rep 2012; 13:170-8.
Apr 1, 2012Therapeutic options for advanced prostate cancer: 2011 update
Apr 1, 2012Curr Urol Rep 2012; 13:170-8
Omlin Aurelius, de Bono Johann S
Targeted therapy in non-small cell lung cancer
Putora P, Schneider T, Rodriguez R, Früh M. Targeted therapy in non-small cell lung cancer. Breathe 2012; 8:206-215.
Mar 16, 2012Targeted therapy in non-small cell lung cancer
Mar 16, 2012Breathe 2012; 8:206-215
Putora Paul Martin, Schneider Tino, Rodriguez Regulo, Früh Martin
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Regan M, Debled M, Maibach R, Price K, Gelber R, Coates A, Goldhirsch A, Rae J, Viale G, Neven P, Ditzel H, Lyng M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104:441-51.
Mar 6, 2012CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Mar 6, 2012J Natl Cancer Inst 2012; 104:441-51
Regan Meredith M, Debled Marc, Maibach Rudolf, Price Karen N, Gelber Richard D, Coates Alan S, Goldhirsch Aron, Rae James M, Viale Giuseppe, Neven Patrick, Ditzel Henrik J, Lyng Maria B, Leyland-Jones Brian, Bouzyk Mark, Pagani Olivia, Tang Weining, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, Breast International Group (BIG) 1-98 Collaborative Group
Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial
Korfel A, Birnbaum T, Kirchen H, Mergenthaler H, Schubert J, Berdel W, Birkmann J, Hummel M, Thiel E, Leithäuser M, Hundsberger T, Weller M, Martus P, Roth P, Klasen H, Roeth A, Rauch M, Hertenstein B, Fischer T, Fischer L. Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. Ann Oncol 2012; 23:2374-2380.
Mar 5, 2012Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial
Mar 5, 2012Ann Oncol 2012; 23:2374-2380
Korfel A, Birnbaum T, Kirchen H, Mergenthaler H-G, Schubert J, Berdel W, Birkmann J, Hummel M, Thiel E, Leithäuser M, Hundsberger Thomas, Weller M, Martus P, Roth P, Klasen H A, Roeth A, Rauch M, Hertenstein B, Fischer T, Fischer L
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients
Solomayer E, Wallwiener D, Wackwitz B, Krämer B, Huober J, Becker S, Lück H, Janni W, Hirnle P, Gebauer G, Fehm T. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 2012; 23:2271-2277.
Mar 1, 2012Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients
Mar 1, 2012Ann Oncol 2012; 23:2271-2277
Solomayer E-F, Wallwiener D, Wackwitz B, Krämer B, Huober Jens, Becker S, Lück H-J, Janni W, Hirnle P, Gebauer G, Fehm T
Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?
Hochstrasser A, Benz G, Jörger M, Templeton A, Brutsche M, Früh M. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. Chemotherapy 2012; 58:84-88.
Feb 23, 2012Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?
Feb 23, 2012Chemotherapy 2012; 58:84-88
Hochstrasser Andreas, Benz Gabriel, Jörger Markus, Templeton Arnoud, Brutsche Martin, Früh Martin
Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer
Knauer M, Gnant M, Fitzal F. Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer. Breast Care (Basel) 2012; 7:61-66.
Feb 20, 2012Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer
Feb 20, 2012Breast Care (Basel) 2012; 7:61-66
Knauer Michael, Gnant Michael, Fitzal Florian
Sentinel lymph node procedure leads to upstaging of patients with resectable colon cancer: results of the Swiss prospective, multicenter study sentinel lymph node procedure in colon cancer
Viehl C, Oertli D, Laffer U, Riehle H, Terracciano L, Ochsner A, Langer I, Cecini R, Gueller U, Zuber M. Sentinel lymph node procedure leads to upstaging of patients with resectable colon cancer: results of the Swiss prospective, multicenter study sentinel lymph node procedure in colon cancer. Ann Surg Oncol 2012; 19:1959-65.
Feb 10, 2012Sentinel lymph node procedure leads to upstaging of patients with resectable colon cancer: results of the Swiss prospective, multicenter study sentinel lymph node procedure in colon cancer
Feb 10, 2012Ann Surg Oncol 2012; 19:1959-65
Viehl Carsten T, Oertli Daniel, Laffer Urban, Riehle Hans-Martin, Terracciano Luigi, Ochsner Alex, Langer Igor, Cecini Ramona, Gueller Ulrich, Zuber Markus
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Renner C, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N, Bouabdallah K, Trojan A, Zinzani P, Gressin R, Klingbiel D, Dietrich P, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012; 97:1085-91.
Feb 7, 2012A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Feb 7, 2012Haematologica 2012; 97:1085-91
Renner Christoph, Lohri Andreas, Gyan Emmanuel, Biaggi Christine, Cogliatti Sergio B., Bertoni Francesco, Ghielmini Michele, Brauchli Peter, Ketterer Nicolas, Bouabdallah Krimo, Trojan Andreas, Zinzani Pier Luigi, Gressin Rémy, Klingbiel Dirk, Dietrich Pierre-Yves, Hitz Felicitas, Bargetzi Mario, Mingrone Walter, Martinelli Giovanni, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network
Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate
Jörger M, Ferreri A, Krähenbühl S, Schellens J, Cerny T, Zucca E, Huitema A. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J Clin Pharmacol 2012; 73:240-7.
Feb 1, 2012Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate
Feb 1, 2012Br J Clin Pharmacol 2012; 73:240-7
Jörger Markus, Ferreri Andrés J M, Krähenbühl Stephan, Schellens Jan H M, Cerny Thomas, Zucca Emanuele, Huitema Alwin D R
Cholecystectomy concomitant with laparoscopic gastric bypass: a trend analysis of the nationwide inpatient sample from 2001 to 2008
Worni M, Gueller U, Shah A, Gandhi M, Shah J, Rajgor D, Pietrobon R, Jacobs D, Ostbye T. Cholecystectomy concomitant with laparoscopic gastric bypass: a trend analysis of the nationwide inpatient sample from 2001 to 2008. Obes Surg 2012; 22:220-9.
Feb 1, 2012Cholecystectomy concomitant with laparoscopic gastric bypass: a trend analysis of the nationwide inpatient sample from 2001 to 2008
Feb 1, 2012Obes Surg 2012; 22:220-9
Worni Mathias, Gueller Ulrich, Shah Anand, Gandhi Mihir, Shah Jatin, Rajgor Dimple, Pietrobon Ricardo, Jacobs Danny O, Ostbye Truls
F-18 choline PET does not detect increased metabolism in F-18 fluoroethyltyrosine-negative low-grade gliomas
Roelcke U, Bruehlmeier M, Hefti M, Hundsberger T, Nitzsche E. F-18 choline PET does not detect increased metabolism in F-18 fluoroethyltyrosine-negative low-grade gliomas. Clin Nucl Med 2012; 37:e1-3.
Jan 26, 2012F-18 choline PET does not detect increased metabolism in F-18 fluoroethyltyrosine-negative low-grade gliomas
Jan 26, 2012Clin Nucl Med 2012; 37:e1-3
Roelcke Ulrich, Bruehlmeier Matthias, Hefti Martin, Hundsberger Thomas, Nitzsche Egbert U
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
von Minckwitz G, Blohmer J, Huober J, Hauschild M, Fehm T, Müller B, Denkert C, Loibl S, Nekljudova V, Untch M, German Breast Group, Kunz G, Jackisch C, Gerber B, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366:299-309.
Jan 26, 2012Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
Jan 26, 2012N Engl J Med 2012; 366:299-309
von Minckwitz Gunter, Blohmer Jens-Uwe, Huober Jens, Hauschild Maik, Fehm Tanja, Müller Berit Maria, Denkert Carsten, Loibl Sibylle, Nekljudova Valentina, Untch Michael, German Breast Group, Kunz Georg, Jackisch Christian, Gerber Bernd, Eidtmann Holger, Rezai Mahdi, Fasching Peter A, Tesch Hans, Eggemann Holm, Schrader Iris, Kittel Kornelia, Hanusch Claus, Kreienberg Rolf, Solbach Christine, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups
Covariate pharmacokinetic model building in oncology and its potential clinical relevance
Jörger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J 2012; 14:119-32.
Jan 25, 2012Covariate pharmacokinetic model building in oncology and its potential clinical relevance
Jan 25, 2012AAPS J 2012; 14:119-32
Jörger Markus
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Untch M, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G, German Breast Group (GBG), Hanusch C, Tesch H, Kreienberg R, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J, Hilfrich J, Strumberg D, Fasching P, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13:135-44.
Jan 17, 2012Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Jan 17, 2012Lancet Oncol 2012; 13:135-44
Untch Michael, Gerber Bernd, Rezai Mahdi, Jackisch Christian, Huober Jens, Kühn Thorsten, Nekljudova Valentina, von Minckwitz Gunter, German Breast Group (GBG), Hanusch Claus, Tesch Hans, Kreienberg Rolf, Loibl Sibylle, Bischoff Joachim, Eidtmann Holger, Kaufmann Manfred, Blohmer Jens-Uwe, Hilfrich Jörn, Strumberg Dirk, Fasching Peter A, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group
Brain metastases free survival differs between breast cancer subtypes
Berghoff A, Preusser M, Steger G, Zielinski C, Gnant M, Mader R, Dieckmann K, Fitzal F, Eiter H, Knauer M, Rottenfusser A, Rudas M, Pluschnig U, Dubsky P, De Vries C, Bago-Horvath Z, Bartsch R. Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 2012; 106:440-6.
Jan 10, 2012Brain metastases free survival differs between breast cancer subtypes
Jan 10, 2012Br J Cancer 2012; 106:440-6
Berghoff A, Preusser M, Steger G G, Zielinski C C, Gnant M, Mader R M, Dieckmann K, Fitzal F, Eiter H, Knauer Michael, Rottenfusser A, Rudas M, Pluschnig U, Dubsky P, De Vries C, Bago-Horvath Z, Bartsch R
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Jörger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2012; 22:567-574.
Jan 4, 2012Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Jan 4, 2012Ann Oncol 2012; 22:567-574
Jörger Markus, Matter-Walstra K, Früh Martin, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M